• Home
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Pierre Laneuville
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Luigina Mollica
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Rey Garcia, RN, BSN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Frank Giles
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Karen Seiter
        • Dr. Neil Shah
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Bin Zhang
      • Other CML experts in South America >
        • Dra Beatriz Moiraghi
        • Dr Carolina Pavlovsky
    • Other CML Experts in Europe >
      • Dr. Jane Apperley
      • Dr. Michele Baccarani
      • Pr. Agnès Buzyn
      • Dr. Gabriel Etienne
      • Dr. Marie-Joëlle Mozziconacci
      • Dr. François Guilhot
      • Dr. Eliane Gluckman
      • Dr. Andreas Hochhaus
      • Dr. Martin Müller
      • Dr. Stephen O'Brien
      • Stéphane Prost
      • Dr. Tessa L Holyoake
      • Dr. Hana Klamova
      • Dr. Jeroen J.W.M. Janssen
      • Dr. Franck-Emmanuel Nicolini
      • Dr. Delphine Rea
      • Dr. Johan Richter
      • Dr. Philippe Rousselot
      • Dr. Giuseppe Saglio
      • Dr. François-Xavier Mahon
      • Pr Gregor Verhoef
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML
    • Blood
    • Bone Marrow
    • DNA
    • Immune System >
      • Natural killer cell - NK
      • T Cells
    • JAK2 Gene
    • Treatment response in CML
    • Polymerase Chain Reaction >
      • Dr. Kary Bank Mullis
    • Stem Cells
    • Donor lymphocyte infusion (DLI)
    • Blood-Brain Barrier
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Gleevec (Imatinib)
    • Tasigna (Nilotinib)
    • Sprycel (Dasatinib)
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • Flumatinib
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • HQP1351
    • K0706
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Magnificent (I Believe)
        • Adagio for Strings (Samuel Barber)
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • Virginia Garner
    • Pat Elliott
    • Jan Geissler
    • Kris
    • Nigel
    • Katie
    • Mel Mann
    • Tamera Simonson
    • Hans Loland
    • Alyssa
    • Brown Dudley
    • Erin Havel (Author)
    • Erin Zammett Ruddy
    • Rob Shick
    • Gary Gonzales
    • Ron Robbecke
    • Drew Johnston
    • Angela Tyrrell
    • Doug Jenson
    • Rich Jones
    • Kevin Williams
    • Jean McGlynn
    • Austin Granatowicz
    • Tom Cleaver
    • Others testimonials
    • Some celebrities >
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Tim Holcomb
      • Doris Muramatsu
      • Ryan O'Neal
      • Charlie Schlatter
      • Kelvin Alston
      • Kareem Abdul-Jabar
      • Carlos Carrasco
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Bud Romine - the first patient
    • Kayla Naton (Pregnancy)
    • Suzan Mc Namara and the petition
  • Blogs
    • Access CML Drugs
    • Trey's CML Leukemia Blog
    • Living with CML
    • CMKID's blog – Dislodging the bullet
    • CML Recovery - Stopping KTI
    • Hans's Blog
    • Elizabeth's Blog - my leukemia journey
    • Elizabeth's Blog - Heart of the rose
    • Ian's Blog
    • Joe's Blog
    • Jon's Blog
    • Josh's Blog
    • Mannan's Blog
    • Justin Ozuna's Blog
    • Lindsey's Blog
    • Matt's Blog
    • Matthew's Blog
    • Michelle's Blog
    • Michelle D's Blog
    • Nayree's Blog
    • Rob's Blog
  • News on CML (Chronic myeloid leukemia)
    • English
    • English- Archives 2017-2016
    • English - Archives 2015-2001
    • French (Français)
    • Spanish (Español)
  • Various topics
    • You’ve just been diagnosed
    • History of CML
    • Cure possible for CML? >
      • Hematopoietic stem cell transplantation using single UM171-expanded cord blood
      • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
      • Inhibition of the protein Ezh2 can cure CML?
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
      • PROTAC-mediated Targeted Protein Degradation
      • Inhibition of STAT5 in conjunction with standard TKI therapy
      • CML vaccine
      • Can immunotherapy cure leukemia?
      • Chimeric Antigen Receptor T-Cell Therapy
      • Can genetic sequencing help to cure leukemia?
      • Natural Medicine >
        • Possible cure for CML in Fish Oil
        • Betel leaf may help fight CML
        • Feverfew extract (parthenolide)
        • Can dandelions kill cancer?
        • Can curcumin cure leukemia?
      • Can the new drug CX-5461 cure leukemia?
      • CRISPR-Cas9 gene-editing technique
      • Presence of bcr abl fusion transcripts in healthy individua
      • Math could help cure leukemia
    • Treatment free remission (TFR ) >
      • The French trial called STIM (Stop Imatinib)
      • De-escalation of treatment
      • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
    • CML causes
    • CML and pregnancy
    • Children with CML
    • Food and Drug Interactions
    • Bone marrow transplant
    • CML Blast Crisis treatment
    • Stem cells from umbilical cord blood
    • Mutation T315I
    • Sensitive detection of BCR-ABL1 mutations
    • Elderly patients with CML
    • Living with CML and diabetes
    • Non-adherence of CML patients
    • Vaccination of CMLers
    • Sports with CML
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Professionnel help and literature
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Patient Rights
  • Moral Support
    • Where to get help and support
    • Family support
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • The march toward healing
    • Be happy
    • Dances at the Cancer Research Centre
    • The spoon theory
    • Stronger
    • Magnificent - Beauty of nature
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • SPECIAL Donation
  • About us
    • Guestbook
    • Contact us
Chronic Myeloid Leukemia

ASCO 2010 - American Society of Clinical Oncology - June 2010 - Chicago


ASCO 2010 - Abstracts in CML

VIDEOS

Dr. Sonali Smith talks about some of the advances in chronic myeloid leukemia care coming out of the 2010 ASCO Annual Meeting.                           

2010 ASCO Annual Meeting Research Review Session for Patient Advocates - Session One                                                                                      

ARTICLES

ASCO Update: New Weapons in the Fight Against Chronic Myeloid Leukemia
August 17, 2010, Pharmacy Times

What did you get out of the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO)?
June 11, 2010, Pharmaphorum

PATIENT ASSOCIATIONS

ASCO 2010- Abstracts from the yearly meeting of the American Society of Clinical Oncology
by cmlsupport

SOME INTERESTING ABSTRACTS

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year.

Safety and efficacy of bosutinib (SKI-606) in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) following resistance or intolerance to imatinib (IM). 

Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200. 

Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. 

Phase I trial of AP24534 in patients with refractory chronic myeloid leukemia (CML) and hematologic malignancies. 

Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily. 

Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib. 

Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML). 

Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. 

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg ± IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV. 

Relationship between dasatinib exposure and long-term clinical outcomes in chronic-phase chronic myeloid leukemia (CML-CP) patients.

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.

Population pharmacokinetic (PK) and exposure-response analysis of nilotinib in newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: Results from ENESTnd.

The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL.

BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Safety of omacetaxine mepesuccinate (OM) subcutaneous (SQ) injection for the treatment of chronic myeloid leukemia (CML) patients (pts) resistant or intolerant to tyrosine kinase inhibitors (TKIs): Analysis of two phase II studies.

Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.

BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.

Central nervous system disease and acute myeloid leukemia or chronic myeloid leukemia: Cytogenetic profile.

United States (US) practices for chronic myelogenous leukemia (CML) management compared to other countries: A worldwide observational registry.

Early intensification of imatinib treatment based on precise definition of accelerated phase in patients with chronic myeloid leukemia: Population-based analysis.

Reactivation of latent viral hepatitis infection in patients of chronic myeloid leukemia treated with imatinib mesylate: Experience from a tertiary cancer center in India.

Tuberculosis infection in chronic myeloid leukemia (CML) patients treated with imatinib.

Meta-analysis of cord blood transplantations for indication of leukemia from private umbilical cord blood banks from 1993-2009.

Pulmonary hypertension (PH) in patients (pts) with CML treated with tyrosine kinase inhibitors (TKIs).

The effect of nilotinib on major molecular responses (MMR) compared with imatinib in Japanese patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Results from the Japanese subset of ENESTnd.

Developing an economic model to estimate the cost-effectiveness of first-line treatments for chronic myelogenous leukemia.

Dasatinib compared to imatinib (IM) in patients (pts) with newly diagnosed chronic-phase chronic myelogenous leukemia in chronic phase (CML-CP): Twelve-month efficacy and safety from the phase III DASISION study.

CPX-351: A randomized phase IIb study first-relapse patients younger than age 65.

          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro aviso legal).

Copyright © 2010-2019 CMLeukemia.com
DMCA.com Protection Status